文献速递炎症性肠病

溃疡性结肠炎安慰剂诱导应答与缓解的预测因素

Predictors of Placebo Induction Response and Remission in Ulcerative Colitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-08-25

该研究对GEMINI-1、ACT-1、ACT-2、PURSUIT、ULTRA-2、OCTAVE-1和OCTAVE-2试验中安慰剂治疗患者进行事后汇总分析,评估与临床及内镜安慰剂应答相关的因素。结果显示,血清C反应蛋白和 albumin 水平正常者更易达到临床应答(71/437 [16.3%] vs 49/660 [7.4%];调整OR 2.76;95%CI 1.19-5.41;P=0.018),而Mayo内镜评分3分者较2分者更不易达到临床应答(105/556 [18.8%] vs 179/675 [25.9%];调整OR 0.33;95%CI 0.16-0.68;P=0.003)。临床缓解和直肠出血缓解也观察到类似结果。

要点

  • 血清C反应蛋白和白蛋白正常的溃疡性结肠炎患者安慰剂临床应答率更高。
  • 基线Mayo内镜评分3分者较2分者安慰剂临床应答率更低。
  • 生物标志物和基线内镜严重程度影响溃疡性结肠炎试验中的安慰剂应答率。

核心结论

  • 血清C反应蛋白和白蛋白正常以及基线内镜严重程度影响溃疡性结肠炎临床试验中的安慰剂应答率。
  • 这些发现对溃疡性结肠炎的临床试验设计有启示。

研究设计与样本

  • 对GEMINI-1、ACT-1、ACT-2、PURSUIT、ULTRA-2、OCTAVE-1和OCTAVE-2试验的汇总临床试验数据进行事后分析。

主要发现

  • 血清C反应蛋白和白蛋白正常的安慰剂治疗患者更可能达到临床应答(71/437 [16.3%] vs 49/660 [7.4%];调整OR 2.76;95%CI 1.19-5.41;P=0.018)。
  • 与Mayo内镜评分2分的患者相比,Mayo内镜评分3分的患者更不可能达到临床应答(105/556 [18.8%] vs 179/675 [25.9%];调整OR 0.33;95%CI 0.16-0.68;P=0.003)。
  • 临床缓解和直肠出血缓解也观察到类似结果。

关键数值与推荐

  • 临床应答定义:总Mayo评分较基线降低≥3分且≥30%,同时直肠出血亚评分(RBS)降低≥1分或RBS绝对值≤1。
  • 临床缓解定义:总Mayo评分≤2且无亚评分>1。
  • 内镜愈合定义:Mayo内镜亚评分≤1。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: High placebo response rates in clinical trials of ulcerative colitis (UC) have been reported previously. However, data from patient-level analyses are lacking. We assessed factors associated with clinical and endoscopic placebo response among placebo-treated patients in clinical trials of UC. METHODS: We performed a post hoc analysis of pooled clinical trial data from GEMINI-1, ACT-1, ACT-2, PURSUIT, ULTRA-2, OCTAVE-1, and OCTAVE-2. Predictors were assessed in placebo-treated patients for their association with end of induction (week 6 of 8) clinical response (reduction in total Mayo score of ≥3 and ≥30% from baseline with ≥1 point decrease in rectal bleeding subscore [RBS] or absolute RBS ≤1); clinical remission (total Mayo score ≤2 and no subscore >1); endoscopic healing (Mayo endoscopic subscore ≤1); partial Mayo score of 0; patient-reported outcome 2-item remission (RBS of 0 and stool frequency ≤1), resolution of rectal bleeding, and stool frequency normalization. Predictors on univariate analyses with P < .05 were included in multivariate logistic regression models. RESULTS: Placebo-treated patients with normal serum C-reactive protein and albumin levels were more likely to attain clinical response (71 of 437 [16.3%] vs 49 of 660 [7.4%]; adjusted odds ratio, 2.76; 95% confidence interval, 1.19-5.41; P = .018). Compared with patients with a Mayo endoscopic score of 2, patients with a Mayo endoscopic score of 3 were less likely to attain clinical response (105 of 556 [18.8%] vs 179 of 675 [25.9%]; adjusted odds ratio, 0.33; 95% confidence interval, 0.16-0.68; P = .003). Similar findings were observed for clinical remission and resolution of rectal bleeding. CONCLUSIONS: Biomarkers such as normal serum C-reactive protein and albumin and baseline endoscopic severity were found to affect placebo response rates in clinical trials of UC. These findings have implications for clinical trial design in UC.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Wong ECL, Dulai PS, Marshall JK, et al. Predictors of Placebo Induction Response and Remission in Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022. PMID: 36029969. doi:10.1016/j.cgh.2022.08.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。